ClinicalTrials.gg
CompletedNCT06781827Updated Oct 28, 2026

Research on the Use of Probiotics in the Prevention and Treatment of Inflammatory Bowel Disease

An interventional study of Probiotic in Inflammatory Bowel Disease, sponsored by Wecare Probiotics Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Wecare Probiotics Co., Ltd. · Not applicable, Interventional, and Prevention

How we know

Updated Oct 28, 2026Now CompletedStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 114 studies in Inflammatory Bowel Diseases with a site in China — 51 open to participants now, 55 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.

Enrollment
49th of 60
41 · median 97
Started
2025
with 25 others
No phase
28 of 114
16 open now
Registered
74th of 114
by date

Among the 114 studies in Inflammatory Bowel Diseases with a site in China, this one is the 49th largest by enrollment of the 60 interventional ones that give a count, is one of 26 that started in 2025, is one of 28 with no phase, and was the 74th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

51 of the 114 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Inflammatory Bowel Diseases with a site in China, or all of them as a file.
02

Study summary

This study evaluates oral Lactobacillus reuteri as an adjunct therapy for 2 months. Endoscopic assessments will be performed at baseline and after 2 months of intervention to evaluate intestinal inflammation. Intestinal fluid samples will be collected during endoscopy for 16S rRNA gene sequencing to assess changes in the gut microbiota. Peripheral blood inflammatory markers and fecal calprotectin levels will also be measured to evaluate changes in intestinal inflammation.

03

Conditions studied

  • Inflammatory Bowel Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be over 18 years old
  2. Agree to sign ; Have been diagnosed with IBD for at least 3 months but not more than 3 years -

Exclusion criteria

Exclusion Criteria:

  1. Does not meet the diagnostic criteria of CD
  2. Patients with other diseases, infectious diseases and malignant tumors Patients with CD during pregnancy and lactation; Patients with serious diseases of the liver, kidney, heart and lung, etc
  3. Patients with allergic diseases such as asthma and allergic rhinitis; alcoholic Patients with mental illness
  4. Patients with suspected cancer in their intestines
  5. Antibiotics, probiotics and prebiotics have been used in the past three months Had intestinal surgery (except appendicitis surgery)
  6. There is currently an infection
  7. He has had cancer in the last 5 years -
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Probiotic

    Daily intervention with Limosilactobacillus reuteri LR08 (10 billion CFU) for 8 weeks, stored in a cool and dry place.

    Dietary Supplement: Probiotic

Interventions

  • Dietary supplementProbiotic

    The experimental phase of the study lasts 8 weeks and each patient will be visited 4 times.

06

What researchers measure

Primary outcomes

  1. Change in Intestinal Inflammation

    Intestinal inflammation will be assessed using the Simple Endoscopic Score for Crohn's Disease (SES-CD) in patients with Crohn's disease and the Mayo Score in patients with ulcerative colitis. SES-CD scores range from 0 to 56, and Mayo scores range from 0 to 12. Higher scores indicate more severe disease activity.

    Time frame: 8 weeks

07

Study locations

1 site
  • Gastroenterology Department of Jiangsu Province (Suqian)Hospital
    Suqian, Jiangsu 223800, China
08

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Mar 2026, 14 months.

Of 299 interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 14 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Oct 2025 → Mar 2026 and completion Dec 2025 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Jan 17, 2025
StartActual
Jan 25, 2025
Primary completionActual
Mar 30, 2026was Oct 2025
CompletionActual
Jun 30, 2026was Dec 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 19, 2026
Start date
Jan 1, 2025→Jan 25, 2025
Oct 28, 2026
Primary completion
Oct 30, 2025→Mar 30, 2026 (actual)
Oct 19, 2026
Study completion
Dec 30, 2025→Jun 30, 2026 (actual)
Oct 19, 2026
Enrollment
50 (estimated)→41 (actual)
Oct 19, 2026
Interventions
Removed Dietary supplement: Maltodextrin. Arms removed: Placebo
Oct 19, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 19, 2026
  • ChangedBefore Improvement of Intestinal Inflammation Assessed by Endoscopic Scoring SystemNow Change in Intestinal InflammationTime frame: 12 months → 8 weeks
What changed on Oct 26, 2026
  • DescriptionChange in Intestinal Inflammation: how it is measured was reworded
across 2 updates, Oct 19, 2026 – Oct 26, 2026
Secondary outcomes
4 removed
What changed in the outcomes
  • RemovedAssessment of Intestinal Flora Changes Using 16S RNA AnalysisTime frame: 8 weeks
  • RemovedAssessment of Inflammatory Changes Using Peripheral Blood Inflammatory MarkersTime frame: 8 weeks
  • RemovedDisease progressionTime frame: 8 weeks
  • RemovedEvaluation of Crohn's Disease Severity Using the Crohn's Disease Activity Index (CDAI)Time frame: 8 weeks
Oct 19, 2026
Show all 3 updates
  1. Oct 28, 2026
    Start date Jan 1, 2025→Jan 25, 2025
  2. Oct 26, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange in Intestinal Inflammation: how it is measured was reworded
  3. Oct 19, 2026
    Recruiting→Completed
    Primary completion Oct 30, 2025→Mar 30, 2026 (now actual)
    Study completion Dec 30, 2025→Jun 30, 2026 (now actual)
    Enrollment 50 (estimated)→41 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Improvement of Intestinal Inflammation Assessed by Endoscopic Scoring SystemNow Change in Intestinal InflammationTime frame: 12 months → 8 weeks
    Secondary outcomes 4 removed
    What changed in the outcomes
    • RemovedAssessment of Intestinal Flora Changes Using 16S RNA AnalysisTime frame: 8 weeks
    • RemovedAssessment of Inflammatory Changes Using Peripheral Blood Inflammatory MarkersTime frame: 8 weeks
    • RemovedDisease progressionTime frame: 8 weeks
    • RemovedEvaluation of Crohn's Disease Severity Using the Crohn's Disease Activity Index (CDAI)Time frame: 8 weeks
    Interventions Removed Dietary supplement: Maltodextrin. Arms removed: Placebo
    + 6 other changes: verification date, description, design details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06781827
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Jan 25, 2025
Primary completion
Mar 30, 2026
Completion
Jun 30, 2026
Last update
Oct 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion